Become a member of BioTechniques (it's free!) and receive the latest news in the life sciences, member-exclusives and 10% off BioTechniques article processing fees

Catching up with COVID-19: producing the first SARS-CoV-2 spike proteins

Written by Tristan Free (Digital Editor)

SARS-CoV-2 spike proteins

In the first of our new feature series of articles, exploring the stories behind key moments in scientific discovery, we reveal the tale of the production of the first commercially available SARS-CoV-2 spike proteins and the fortuitous circumstances that led to their creation.  As the COVID-19 pandemic gained momentum at the beginning of 2020, researchers were in desperate need of viral proteins to better understand the disease and its pathogenesis. As the scientific community scrambled to get this information together, a combination of serendipity and good prior planning meant that one Oxford (UK) based company was ahead of the game: The Native Antigen Company.  ...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!